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Background:   Heart failure (HF) is a clinical syndrome; preclinical stages based on HF risk factors (stage A HF) and subclinical cardiac 
dysfunction (SBHF) are considered asymptomatic. We sought whether risk of overt HF in these conditions is associated with perceived 
wellbeing, cardiac functional abnormalities and functional capacity.
methods:   We recruited 426 community individuals (age 71±5y; 48% men; BMI 29.7±5), ≥ 65 years with ≥1 HF risks (hypertension, type 
2 diabetes, obesity, previous chemotherapy and family history of heart disease and previous cardiac history). All subjects underwent 
questionnaires for assessment of activity (Duke Activity Score Index, DASI), symptom status (Minnesota Living with HF, MLHF), quality of 
life (EQ5D), 6-minute walk (6MW), and a comprehensive echocardiogram including Global Longitudinal Strain (GLS). The ARIC HF risk 
score was used to stratify participants into tertiles of HF risk.
results:  Of 426 pts, 19% had one HF risk factor, 39% had two and 42% had >2. The median 4 year risk of overt HF was 6.2%, divided 
into high (>9.4% risk), intermediate (4.3-9.3%) and low (<4.2%) risk tertiles, which differed in symptom status (DASI, MLHF and EQ5D), 
GLS and 6MW distance (Table).
conclusion:  Clinical HF risk status in SAHF and SBHF is significantly related to symptoms, subclinical LV dysfunction and functional 
capacity. These at risk individuals are preclinical but not asymptomatic.
